Comparative Efficacy and Safety of Targeted Therapies for Chronic Thromboembolic Pulmonary Hypertension: A Systematic Review and Network Meta-Analysis

Table 2

Ranking of PAH-targeted drugs for CTEPH assessed by estimated and predictive probabilities using SUCRA values.

Intervention	SUCRA
	6MWD (%)	BNP (%)	NYHA/WHO FC improvement (%)	PVR (%)	Clinical worsening (%)
Placebo	14.7	11.2	9.0	5.0	12.1
Bosentan	24.2	84.3	63.2	48.4	42.8
Sildenafil	45.6	43.4	87.3	54.9	—
Riociguat	80.4	45.4	50.7	77.4	63.3
Macitentan	64.0	49.8	17.3	33.9	79.2
Ambrisentan	46.4	—	—	—	—
Treprostinil	74.6	65.9	72.5	86.2	52.6
Iloprost	—	—	—	44.2	—

Higher estimated probabilities of SUCRA close to 100% indicate superiority over other therapies, whereas lower values close to 0% indicate inferiority.